mergers & acquisitions

Cell Biosciences will pay Alpha Innotech's shareholders $1.50 per share, giving the deal a total consideration of $17.9 million.

The Belgian life sciences company sees the acquisition as bringing together the firm's respective genomics and proteomics capabilities and their European and US presences.

BD plans to place its GeneOhm assays on HandyLab's Jaguar system.

MDS' shareholders voted in favor of the deal at a special meeting on Tuesday.

OriGene gains products for DNA and RNA purification and multiplex assays for genotyping, microRNA profiling, and transcription factor activity analysis.

BGIP sells a range of bioscience products that are "tailored" to the Indian market, said the German firm.

Silence said that it "expects the proposed transaction to be treated as a reverse takeover … [and will be] subject to due diligence and would be conditional upon shareholder approval."

While CombiMatrix did not disclose the terms within which a recently hired investment bank will serve as its "financial and strategic advisor," such moves typically are overtures to mergers, acquisitions, or asset divestitures.

The deal caps months of speculation about Life Tech's plans for the AB Sciex mass spec business following the merger of Invitrogen and ABI last November to create the firm.

LabCorp completed its $107 million purchase of Monogram this week.


An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.